Valuation: Wockhardt Limited

Market Cap 310B 3.25B 2.82B 2.63B 2.41B 4.53B 4.6B 30.87B 12.11B 155B 12.22B 11.95B 517B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 326B 3.42B 2.96B 2.76B 2.53B 4.76B 4.83B 32.41B 12.72B 163B 12.83B 12.55B 543B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day-1.13%
1 week-5.87%
Current month-2.57%
1 month+5.45%
3 months+18.85%
6 months+33.61%
Current year+32.03%
1 week 1,900.1
Extreme 1900.1
2,056.9
1 month 1,792.4
Extreme 1792.4
2,067.7
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%-5.87%+29.70%+644.26% 3.29B
-0.12%-1.09%+22.38%+68.83% 48.92B
-1.14%+9.22%+60.80%+124.81% 41.53B
-0.32%-0.77%-1.53%+16.21% 12.43B
+6.43%+6.24%+27.22%+81.04% 11.7B
+0.77%-0.38%+30.98%+137.44% 9.09B
+1.95%+9.12%+25.38%+40.22% 7.4B
+1.62%+3.49%+41.67%-13.45% 7.15B
+1.10%+2.06%+12.70%+180.85% 6.66B
-1.22%+7.23%-25.51%+28.75% 5.95B
Average +0.79%+3,563.42%+22.38%+130.90% 15.41B
Weighted average by Cap. +0.31%+4,959.49%+30.60%+95.03%

Financials

2025 2026
Net sales 30.35B 318M 275M 257M 235M 443M 450M 3.02B 1.18B 15.18B 1.19B 1.17B 50.57B 34.62B 363M 314M 294M 268M 506M 514M 3.44B 1.35B 17.32B 1.36B 1.33B 57.68B
Net income -470M -4.93M -4.27M -3.99M -3.64M -6.87M -6.98M -46.76M -18.35M -235M -18.5M -18.1M -783M 2.13B 22.33M 19.33M 18.07M 16.52M 31.12M 31.61M 212M 83.15M 1.07B 83.86M 82.03M 3.55B
Net Debt 14.33B 150M 130M 122M 111M 209M 213M 1.43B 559M 7.17B 564M 552M 23.88B 15.53B 163M 141M 132M 120M 227M 230M 1.55B 606M 7.77B 611M 598M 25.88B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-08-11 1,909.40 -1.13% 1,073,711
26-08-10 ₹1,931.20 -4.44% 1,702,030
26-08-07 ₹2,021.00 +2.33% 547,985
26-08-06 ₹1,975.00 -1.55% 578,202
26-08-05 ₹2,006.10 -0.82% 863,920
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock